Frank Rimerman Advisors LLC raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 25,673.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,794 shares of the company's stock after purchasing an additional 9,756 shares during the period. Frank Rimerman Advisors LLC's holdings in AstraZeneca were worth $764,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of AZN. Price T Rowe Associates Inc. MD lifted its position in AstraZeneca by 17.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company's stock valued at $4,151,177,000 after purchasing an additional 9,002,450 shares during the period. Sanders Capital LLC boosted its stake in shares of AstraZeneca by 39.0% in the 4th quarter. Sanders Capital LLC now owns 14,684,066 shares of the company's stock worth $988,972,000 after buying an additional 4,122,965 shares during the last quarter. Swedbank AB bought a new stake in shares of AstraZeneca in the first quarter worth $186,127,000. Manning & Napier Advisors LLC purchased a new stake in AstraZeneca during the second quarter valued at $188,476,000. Finally, Hsbc Holdings PLC lifted its holdings in AstraZeneca by 750.3% in the second quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company's stock valued at $100,523,000 after acquiring an additional 1,132,362 shares during the period. Institutional investors own 20.35% of the company's stock.
AZN has been the subject of several research reports. TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Monday, August 12th. Argus increased their price target on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a "buy" rating in a research report on Thursday, May 30th. Barclays raised shares of AstraZeneca to a "strong-buy" rating in a research report on Monday, June 24th. Erste Group Bank raised AstraZeneca from a "hold" rating to a "buy" rating in a report on Wednesday, September 11th. Finally, The Goldman Sachs Group assumed coverage on AstraZeneca in a report on Thursday, May 30th. They set a "buy" rating and a $97.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $89.75.
View Our Latest Report on AstraZeneca
NASDAQ:AZN opened at $77.14 on Tuesday. The business's 50-day simple moving average is $81.80 and its two-hundred day simple moving average is $76.73. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The stock has a market cap of $239.17 billion, a PE ratio of 37.81, a P/E/G ratio of 1.49 and a beta of 0.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.01. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The company had revenue of $12.45 billion for the quarter, compared to analysts' expectations of $12.62 billion. During the same period in the previous year, the firm earned $1.08 EPS. The firm's revenue was up 9.1% compared to the same quarter last year. As a group, analysts forecast that AstraZeneca PLC will post 4.05 EPS for the current fiscal year.
The business also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Shareholders of record on Friday, August 9th were paid a $0.49 dividend. This represents a yield of 1.8%. The ex-dividend date was Friday, August 9th. AstraZeneca's payout ratio is currently 48.04%.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.